Naoko Ishiguro

Naoko Ishiguro

Auto-generated profile, based on publicly available information

Naoko Ishiguro

Department of Dermatology Tokyo Women's Medical University Tokyo Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2014 in Rheumatology
Verified
Journal Article
Open access
PDF file
HYHisashi Yamanaka
Hisashi Yamanaka
NINaoki Ishiguro
Naoki Ishiguro
TTTsutomu Takeuchi
Tsutomu Takeuchi
NMNaoyuki Miyasaka
Naoyuki Miyasaka
MMMasaya Mukai
Masaya Mukai
YTYoshiya Tanaka
Yoshiya Tanaka
Objective. The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods. Patients completing the 26-week, randomized, placebo-controlled trial of adalimumab + MTX were eligible to receive 26 weeks of open-label adalimumab + MTX. Patients were assessed for mean change from baseline in the 28-joint DAS with ESR (DAS28-ESR) and modified total Sharp score (mTSS), and for the proportions of patients achieving clinical, functional or radiographic remission. Results. Of 333 patients assessed, 278 (137 from the initial adalimumab + MTX and 141 from the initial placebo + MTX groups) completed the 52-week study. Significant differences in clinical and functional parameters observed during the 26-week blinded period were not apparent following the addition of open-label adalimumab to MTX. Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups, but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks (mean ΔmTSS at week 52 = 2.56 vs 3.30, P < 0.001). Conclusion. Delayed addition of adalimumab in Japanese MTX-naive early RA patients did not impact clinical and functional outcomes at week 52 compared with the earlier addition of adalimumab. However, the accrual of significant structural damage during blinded placebo + MTX therapy contributed to the persistence of differences between the treatment strategies, suggesting that Japanese patients at risk for aggressive disease should benefit from the early inclusion of adalimumab + MTX combination therapy. Trial registration. ClinicalTrials.gov ( http://clinicaltrials.gov/ ), NCT00870467.

17 March 2025 in Experimental Dermatology
Verified
Journal Article
Closed access
AMAkiko Mochizuki
Akiko Mochizuki
TOToshifumi Osaka
Toshifumi Osaka
YFYasuko Fukuya
Yasuko Fukuya
NYNaoko Yanagisawa
Naoko Yanagisawa
NINaoko Ishiguro
Naoko Ishiguro

4 July 2023 in Experimental Dermatology
Verified
Journal Article
Closed access
STShiho Tanaka
Shiho Tanaka
HSHiroaki Sakaue
Hiroaki Sakaue
TKToshikazu Koiwai
Toshikazu Koiwai
NONatsuki Okuda
Natsuki Okuda
KOKatsuki Okuyama
Katsuki Okuyama
TSTakashi Sato
Takashi Sato

28 October 2021 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RMRyujin Miyata
Ryujin Miyata
CMChie Miyabe
Chie Miyabe
YFYasuko Fukuya
Yasuko Fukuya
NTNorina Tanaka
Norina Tanaka
JTJunji Tanaka
Junji Tanaka
NINaoko Ishiguro
Naoko Ishiguro

14 July 2021 in Journal of Cutaneous Immunology and Allergy
Verified
Journal Article
Open access
PDF file
MSMeiko Sone
Meiko Sone
CMChie Miyabe
Chie Miyabe
RMRyujin Miyata
Ryujin Miyata
YTYuko Takenaka
Yuko Takenaka
NINaoko Ishiguro
Naoko Ishiguro
Eosinophilic granulomatosis with polyangiitis (EGPA) belongs to the family of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis syndromes. Although increasing evidence indicates the correlation of clinical and histological features with the presence or absence of ANCAs in EGPA, the variations in cutaneous features according to their ANCA status have not been fully described. Here, we retrospectively reviewed the clinical and histological findings of 9 cases of EGPA, who presented with cutaneous lesions. Our data indicate that ANCA-positive patients often present with blisters, systemic inflammatory symptoms, and are prone to receive a higher dose of oral prednisolone and additional immunosuppressive therapies.

10 October 2023 in Experimental Dermatology
Verified
Journal Article
Closed access
STShiho Tanaka
Shiho Tanaka
HSHiroaki Sakaue
Hiroaki Sakaue
TKToshikazu Koiwai
Toshikazu Koiwai
NONatsuki Okuda
Natsuki Okuda
KOKatsuki Okuyama
Katsuki Okuyama
TSTakashi Sato
Takashi Sato